Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hereditary Angioedema (HAE) Therapeutics Market

Hereditary Angioedema (HAE) Therapeutics Market Share

Report ID: GMI11102
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Hereditary Angioedema Therapeutics Market Share

The market is characterized by intense competition among key players aiming to expand their market presence. Leading companies focus on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. These efforts aim to enhance their product and service offerings, expand their geographic reach, and invest in advanced technologies. The market also witnesses the entry of new players, further intensifying the competitive landscape.

Hereditary Angioedema Therapeutics Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the market are as mentioned below:

Attune Pharmaceuticals
BioCryst Pharmaceuticals, Inc.
Biomarin
CSL Behring LLC
Intellia Therapeutics
Ionis Pharmaceuticals
KalVista Pharmaceuticals, Inc.
Pharming Healthcare, Inc.
Pharvaris
Takeda Pharmaceutical Company Ltd

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global hereditary angioedema therapeutics industry was valued at USD 4.1 billion in 2023 and is anticipated to register 9.2% CAGR between 2024 and 2032 due to the rising awareness of hereditary angioedema and advancements in diagnostic technology.

The hospital pharmacies segment in the market is predicted to record 9.5% CAGR through 2032 due to their expertise in managing HAE therapies and providing essential diagnostic tools for ensuring proper treatment and accurate diagnoses.

Asia Pacific hereditary angioedema therapeutics market held 46.8% revenue share in 2023 due to its strong research and development infrastructure and expanded access to specialized care.

Attune Pharmaceuticals, BioCryst Pharmaceuticals, Inc., Biomarin, CSL Behring LLC, Intellia Therapeutics, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Inc., Pharming Healthcare, Inc., and Pharvaris, among others.